Prognostic Significance of Preoperative Sarcopenia in Patients With Gastric Cancer Liver Metastases Receiving Hepatectomy

Overview

Journal Front Nutr

Specialty Nutritional Sciences

Date 2022 May 27

PMID 35619951

Authors

Jianping Xiong

Yunzi Wu

Haitao Hu

Wenzhe Kang

Yang Li

Peng Jin

Xinxin Shao

Weikun Li

Yantao Tian

Affiliations

Soon will be listed here.

Abstract

Background: The present work focused on assessing the role of computed tomography (CT)-determined sarcopenia in the prognosis of patients with gastric cancer liver metastases (GCLM) receiving hepatectomy.

Methods: We analyzed data collected from GCLM cases that underwent hepatectomy between March 2011 and July 2017. The third lumbar vertebra (L3) level skeletal muscle index (SMI) was analyzed by abdominal CT to determine the sarcopenia before surgery. The thresholds for CT-based sarcopenia of sex-specific L3 SMI were ≤ 34.9 cm/m and ≤ 40.8 cm/m for female and male, separately We determined overall survival (OS) and recurrence-free survival (RFS)by univariate and multivariate analyses.

Results: The cohort enrolled altogether 114 patients with GCLM receiving hepatectomy (average age: 62.6 years, male: 79.8%), and 58 (50.8%) patients had sarcopenia. The mean SMI was 34.2 in patients with sarcopenia compared to 42.7 in patients without sarcopenia ( < 0.001). The 1-, 3-, and 5-year OS rates in patients with GCLM after hepatectomy were 78.1, 43.7, and 34.3%, respectively. The 1-, 3-, and 5-year RFS rates in patients were 49.8, 33.6, and 29.3%, respectively. Sarcopenia was related to an advanced age (≥65.0 years) ( = 0.009), reduced BMI (<18.5 kg/m) ( < 0.001) and number of liver metastases (>1) ( = 0.025). Sarcopenia had a significant associated with the patterns of recurrence ( < 0.001). In addition, patients with sarcopenia had a significant difference in number of liver metastases in comparison with those without sarcopenia ( = 0.025). We discovered from multivariate analysis that sarcopenia independently predicted RFS [hazard ratio () = 1.76; 95% confidence interval ()= 1.18-2.35, = 0.007]. Nevertheless, sarcopenia was not the prognostic factors that independently predicted OS ( = 1.62; 95% = 0.57-2.73; = 0.330).

Conclusions: In conclusion, we showed that CT-determined sarcopenia was the facile and effective prognostic factor for RFS inpatients with GCLM after hepatectomy. Patients with sarcopenia are associated with an increased tumor recurrence risk, and thereby customized treatment should be applied.

Citing Articles

Development and validation of a nomogram to predict the survival and estimate surgical benefits for gastric cancer with liver metastasis receiving primary tumor resection.

Su R, Sun X, Chen S, Deng G, Yin S, He Y Front Oncol. 2024; 14:1418548.

PMID: 39582532 PMC: 11581971. DOI: 10.3389/fonc.2024.1418548.

The Effects of Sarcopenia on Overall Survival and Postoperative Complications of Patients Undergoing Hepatic Resection for Primary or Metastatic Liver Cancer: A Systematic Review and Meta-Analysis.

Giakoustidis A, Papakonstantinou M, Chatzikomnitsa P, Gkaitatzi A, Bangeas P, Loufopoulos P J Clin Med. 2024; 13(13).

PMID: 38999435 PMC: 11242440. DOI: 10.3390/jcm13133869.

Effect of sarcopenia and frailty on outcomes among patients with brain metastases.

Lim M, Zhang Z, Zheng Y, Khoo I, Ying R, Koh S J Neurooncol. 2024; 167(1):169-180.

PMID: 38430419 DOI: 10.1007/s11060-023-04542-w.

Peking prognostic score is a useful prognostic factor in patients with gastric cancer liver metastases receiving hepatectomy.

Xiong J, Wu Y, Hu H, Kang W, Li Y, Jin P Front Nutr. 2022; 9:976364.

PMID: 36245530 PMC: 9562039. DOI: 10.3389/fnut.2022.976364.

References

Dodson S, Baracos V, Jatoi A, Evans W, Cella D, Dalton J . Muscle wasting in cancer cachexia: clinical implications, diagnosis, and emerging treatment strategies. Annu Rev Med. 2010; 62:265-79. DOI: 10.1146/annurev-med-061509-131248. View

Kim Y, Lee J, Jeong W, Kim S, Kim J, Hong J . Prognostic significance of sarcopenia in microsatellite-stable gastric cancer patients treated with programmed death-1 inhibitors. Gastric Cancer. 2020; 24(2):457-466. DOI: 10.1007/s10120-020-01124-x. View

Markar S, Mikhail S, Malietzis G, Athanasiou T, Mariette C, Sasako M . Influence of Surgical Resection of Hepatic Metastases From Gastric Adenocarcinoma on Long-term Survival: Systematic Review and Pooled Analysis. Ann Surg. 2016; 263(6):1092-101. DOI: 10.1097/SLA.0000000000001542. View

Bajric T, Kornprat P, Faschinger F, Werkgartner G, Mischinger H, Wagner D . Sarcopenia and primary tumor location influence patients outcome after liver resection for colorectal liver metastases. Eur J Surg Oncol. 2021; 48(3):615-620. DOI: 10.1016/j.ejso.2021.09.010. View

Montagnani F, Crivelli F, Aprile G, Vivaldi C, Pecora I, De Vivo R . Long-term survival after liver metastasectomy in gastric cancer: Systematic review and meta-analysis of prognostic factors. Cancer Treat Rev. 2018; 69:11-20. DOI: 10.1016/j.ctrv.2018.05.010. View

Oki E, Tokunaga S, Emi Y, Kusumoto T, Yamamoto M, Fukuzawa K . Surgical treatment of liver metastasis of gastric cancer: a retrospective multicenter cohort study (KSCC1302). Gastric Cancer. 2015; 19(3):968-76. DOI: 10.1007/s10120-015-0530-z. View

Cheon S, Rha S, Jeung H, Im C, Kim S, Kim H . Survival benefit of combined curative resection of the stomach (D2 resection) and liver in gastric cancer patients with liver metastases. Ann Oncol. 2008; 19(6):1146-53. DOI: 10.1093/annonc/mdn026. View

Zhuang C, Huang D, Pang W, Zhou C, Wang S, Lou N . Sarcopenia is an Independent Predictor of Severe Postoperative Complications and Long-Term Survival After Radical Gastrectomy for Gastric Cancer: Analysis from a Large-Scale Cohort. Medicine (Baltimore). 2016; 95(13):e3164. PMC: 4998538. DOI: 10.1097/MD.0000000000003164. View

Takemura N, Saiura A, Koga R, Arita J, Yoshioka R, Ono Y . Long-term outcomes after surgical resection for gastric cancer liver metastasis: an analysis of 64 macroscopically complete resections. Langenbecks Arch Surg. 2012; 397(6):951-7. DOI: 10.1007/s00423-012-0959-z. View

10.

Strasberg S, Phillips C . Use and dissemination of the brisbane 2000 nomenclature of liver anatomy and resections. Ann Surg. 2012; 257(3):377-82. DOI: 10.1097/SLA.0b013e31825a01f6. View

11.

Kang S, Jeong W, Baik S, Cha S, Kim M . Impact of sarcopenia on prognostic value of cirrhosis: going beyond the hepatic venous pressure gradient and MELD score. J Cachexia Sarcopenia Muscle. 2018; 9(5):860-870. PMC: 6204582. DOI: 10.1002/jcsm.12333. View

12.

Kinoshita T, Saiura A, Esaki M, Sakamoto H, Yamanaka T . Multicentre analysis of long-term outcome after surgical resection for gastric cancer liver metastases. Br J Surg. 2014; 102(1):102-7. DOI: 10.1002/bjs.9684. View

13.

Rinninella E, Cintoni M, Raoul P, Pozzo C, Strippoli A, Bria E . Muscle mass, assessed at diagnosis by L3-CT scan as a prognostic marker of clinical outcomes in patients with gastric cancer: A systematic review and meta-analysis. Clin Nutr. 2019; 39(7):2045-2054. DOI: 10.1016/j.clnu.2019.10.021. View

14.

Chen L, Woo J, Assantachai P, Auyeung T, Chou M, Iijima K . Asian Working Group for Sarcopenia: 2019 Consensus Update on Sarcopenia Diagnosis and Treatment. J Am Med Dir Assoc. 2020; 21(3):300-307.e2. DOI: 10.1016/j.jamda.2019.12.012. View

15.

Yang Z, Zhou X, Ma B, Xing Y, Jiang X, Wang Z . Predictive Value of Preoperative Sarcopenia in Patients with Gastric Cancer: a Meta-analysis and Systematic Review. J Gastrointest Surg. 2018; 22(11):1890-1902. DOI: 10.1007/s11605-018-3856-0. View

16.

Markar S, Mackenzie H, Mikhail S, Mughal M, Preston S, Maynard N . Surgical resection of hepatic metastases from gastric cancer: outcomes from national series in England. Gastric Cancer. 2016; 20(2):379-386. DOI: 10.1007/s10120-016-0604-6. View

17.

Waalboer R, Meyer Y, Galjart B, Olthof P, van Vugt J, Grunhagen D . Sarcopenia and long-term survival outcomes after local therapy for colorectal liver metastasis: a meta-analysis. HPB (Oxford). 2021; 24(1):9-16. DOI: 10.1016/j.hpb.2021.08.947. View

18.

van Dijk D, Krill M, Farshidfar F, Li T, Rensen S, Olde Damink S . Host phenotype is associated with reduced survival independent of tumour biology in patients with colorectal liver metastases. J Cachexia Sarcopenia Muscle. 2018; 10(1):123-130. PMC: 6438330. DOI: 10.1002/jcsm.12358. View

19.

Yang M, Shen Y, Tan L, Li W . Prognostic Value of Sarcopenia in Lung Cancer: A Systematic Review and Meta-analysis. Chest. 2019; 156(1):101-111. DOI: 10.1016/j.chest.2019.04.115. View

20.

Takenaka Y, Oya R, Takemoto N, Inohara H . Predictive impact of sarcopenia in solid cancers treated with immune checkpoint inhibitors: a meta-analysis. J Cachexia Sarcopenia Muscle. 2021; 12(5):1122-1135. PMC: 8517360. DOI: 10.1002/jcsm.12755. View